Aurobindo Pharma Limited Market Cap ($10.46 Billion)
Market Cap & Net Worth: Aurobindo Pharma Limited (AUROPHARMA)
Aurobindo Pharma Limited market cap. Aurobindo Pharma Limited (NSE:AUROPHARMA) has a market capitalization of $10.46 Billion (Rs967.44 Billion) as of November 1, 2026. Listed on the NSE stock exchange, this India-based company holds position #2088 globally and #85 in its home market, demonstrating a 4.38% increase in market value over the past year.
Market capitalization, also known as net worth in stock markets, is calculated by multiplying Aurobindo Pharma Limited's stock price Rs1681.40 by its total outstanding shares 575377895 (575.38 Million). Also see Aurobindo Pharma Limited cash flow conversion for how efficiently the company converts equity into cash flow.
Aurobindo Pharma Limited Market Cap History (2015–2026)
Aurobindo Pharma Limited market cap history from 2015 to 2026. Data shows growth from $5.18 Billion to $10.46 Billion (7.38% CAGR). Check latest Aurobindo Pharma Limited stock price today for real-time trading data and today's change.
Index Memberships
Aurobindo Pharma Limited is a constituent of 12 market indices:
| Index | Total Market Cap | Weight (%) | Rank by Market Cap |
|---|---|---|---|
|
NIFTY PHARMA
CNXPHARMA
|
$103.57 Billion | 10.10% | #5 of 20 |
|
NIFTY GROWTH SECTORS 15
NI15
|
$239.63 Billion | 4.37% | #9 of 15 |
|
NIFTY MIDCAP 100
NIFMDCP100
|
$485.01 Billion | 2.16% | #13 of 100 |
|
NIFTY100 EQUAL WEIGHT
NIFTY100EW
|
$1.66 Trillion | 0.63% | #51 of 99 |
|
NIFTY 200
NIFTY200
|
$2.39 Trillion | 0.44% | #77 of 200 |
|
NIFTY 500
NIFTY500
|
$2.93 Trillion | 0.36% | #80 of 500 |
|
NIFTY HEALTHCARE
NIFTYHEALTHCARE
|
$119.23 Billion | 8.78% | #6 of 20 |
|
NIFTY MIDCAP 150
NIFTYMIDCAP150
|
$647.27 Billion | 1.62% | #15 of 150 |
|
NIFTY MIDCAP SELECT
NIFTYMIDSELECT
|
$157.99 Billion | 6.62% | #6 of 25 |
|
NIFTY MIDSMALLCAP 400
NIFTYMIDSML400
|
$1.06 Trillion | 0.99% | #20 of 400 |
|
NIFTY TOTAL MARKET
NIFTYTOTALMKT
|
$3.02 Trillion | 0.35% | #79 of 750 |
|
NIFTY MIDCAP 50
NIMDCP50
|
$272.02 Billion | 3.85% | #8 of 50 |
Weight: Aurobindo Pharma Limited's market cap as a percentage of total index value. Rank: Position among all constituents by market cap.
Aurobindo Pharma Limited Market Cap to Earnings & Revenue Ratios Timeline
This chart shows how Aurobindo Pharma Limited's valuation ratios have evolved. The Price to Sales (P/S) ratio compares market cap to revenue, while the Price to Earnings (P/E) ratio compares market cap to net income. Lower values may indicate a more undervalued company relative to its financial performance. Explore AUROPHARMA net asset momentum to track how rapidly the company is growing its equity base year over year.
Latest Price to Sales (P/S) Ratio
0.03x
Aurobindo Pharma Limited's market cap is 0.03 times its annual revenue
Latest Price to Earnings (P/E) Ratio
0.30x
Aurobindo Pharma Limited's market cap is 0.30 times its annual earnings
What These Ratios Tell Investors:
- Price to Sales (P/S) Ratio: Shows how much investors are paying for each dollar of the company's sales. Lower P/S ratios may indicate undervaluation.
- Price to Earnings (P/E) Ratio: Shows how much investors are paying for each dollar of the company's earnings. This is one of the most common valuation metrics.
- Trends in these ratios over time can indicate changing investor sentiment about the company's future growth prospects.
- Industry comparison provides context for whether the company is valued higher or lower than peers.
| Year | Market Cap (USD) | Revenue (USD) | Net Income (USD) | P/S Ratio | P/E Ratio |
|---|---|---|---|---|---|
| 2017 | $4.10 Billion | $149.33 Billion | $23.02 Billion | 0.03x | 0.18x |
| 2018 | $4.39 Billion | $164.63 Billion | $24.23 Billion | 0.03x | 0.18x |
| 2019 | $2.75 Billion | $195.64 Billion | $23.65 Billion | 0.01x | 0.12x |
| 2020 | $5.57 Billion | $230.99 Billion | $28.45 Billion | 0.02x | 0.20x |
| 2021 | $4.46 Billion | $247.75 Billion | $53.35 Billion | 0.02x | 0.08x |
| 2022 | $2.70 Billion | $234.55 Billion | $26.48 Billion | 0.01x | 0.10x |
| 2023 | $6.74 Billion | $248.55 Billion | $19.27 Billion | 0.03x | 0.35x |
| 2024 | $8.30 Billion | $290.02 Billion | $31.73 Billion | 0.03x | 0.26x |
| 2025 | $7.36 Billion | $317.24 Billion | $34.86 Billion | 0.02x | 0.21x |
| 2026 | $10.46 Billion | $336.53 Billion | $35.05 Billion | 0.03x | 0.30x |
Competitor Companies of AUROPHARMA by Market Capitalization
Companies near Aurobindo Pharma Limited in the global market cap rankings as of November 1, 2026. Also see total assets of Aurobindo Pharma Limited for a full breakdown of the balance sheet.
Key companies related to Aurobindo Pharma Limited by market ranking:
- Takeda Pharmaceutical Co Ltd ADR (NYSE:TAK): Ranked #511 globally with a market cap of $52.60 Billion USD.
- GALDERMA GROUP AG (NYSE:GALDY): Ranked #535 globally with a market cap of $50.42 Billion USD.
- Jiangsu Hengrui Medicine Co Ltd (SHG:600276): Ranked #593 globally with a market cap of $45.23 Billion USD ( CN¥309.13 Billion CNY).
- Takeda Pharmaceutical Company Limited (F:TKDA): Ranked #619 globally with a market cap of $43.60 Billion USD ( €37.29 Billion EUR).
| Rank | Company | Symbol | Market Cap | Price |
|---|---|---|---|---|
| #511 | Takeda Pharmaceutical Co Ltd ADR | NYSE:TAK | $52.60 Billion | $16.65 |
| #535 | GALDERMA GROUP AG | NYSE:GALDY | $50.42 Billion | $46.62 |
| #593 | Jiangsu Hengrui Medicine Co Ltd | SHG:600276 | $45.23 Billion | CN¥48.46 |
| #619 | Takeda Pharmaceutical Company Limited | F:TKDA | $43.60 Billion | €18.30 |
Market Capitalization of Aurobindo Pharma Limited (2015–2026)
Market capitalization of Aurobindo Pharma Limited from 2015 to today. Between 2015 and today, Aurobindo Pharma Limited's market cap moved from $5.18 Billion to $ 10.46 Billion, with a yearly change of 7.38%.
| Year | Market Cap | Change (%) |
|---|---|---|
| 2026 | Rs10.46 Billion | +42.13% |
| 2025 | Rs7.36 Billion | -11.35% |
| 2024 | Rs8.30 Billion | +23.13% |
| 2023 | Rs6.74 Billion | +150.11% |
| 2022 | Rs2.70 Billion | -39.53% |
| 2021 | Rs4.46 Billion | -19.94% |
| 2020 | Rs5.57 Billion | +102.47% |
| 2019 | Rs2.75 Billion | -37.32% |
| 2018 | Rs4.39 Billion | +7.05% |
| 2017 | Rs4.10 Billion | +3.26% |
| 2016 | Rs3.97 Billion | -23.35% |
| 2015 | Rs5.18 Billion | -- |
End of Day Market Cap According to Different Sources
On Oct 31st, 2026 the market cap of Aurobindo Pharma Limited was reported to be:
| Source | Market Cap |
|---|---|
| Yahoo Finance | $10.46 Billion USD |
| MoneyControl | $10.46 Billion USD |
| MarketWatch | $10.46 Billion USD |
| marketcap.company | $10.46 Billion USD |
| Reuters | $10.46 Billion USD |
Market cap values may vary slightly between sources due to differences in calculation methods, timing, and data refresh rates.
About Aurobindo Pharma Limited
Aurobindo Pharma Limited, a pharmaceutical company, develops, manufactures, and commercializes generic pharmaceuticals in India, the United States, Europe, and internationally. The company manufactures a range of finished formulation products in various forms, such as oral solids, liquids, injectables for generic pharmaceuticals, branded specialty pharmaceuticals, and active pharmaceutical ingred… Read more